<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02328014</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-LY-001</org_study_id>
    <nct_id>NCT02328014</nct_id>
  </id_info>
  <brief_title>ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies</brief_title>
  <official_title>A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerta Pharma BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acerta Pharma BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD), and
      efficacy ACP-196 and ACP 319 in B-cell malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events from the combination of ACP-196 and ACP-319</measure>
    <time_frame>up to 12 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate of the combination of ACP-196 and ACP-319</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Non-hodgkins Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>B-All</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ACP-196 dose will be fixed and the ACP 319 dose will be escalated in each cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will commence once the safety and efficacy results from the dose escalation cohorts of the study indicate further evaluation of the combination is warranted.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACP-196 and ACP-319</intervention_name>
    <description>Dose escalation</description>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACP-196 and ACP-319</intervention_name>
    <description>Dose expansion</description>
    <arm_group_label>Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Diagnosis of a b-cell malignancy as documented by medical records and with histology
             based on criteria established by the World Health Organization (WHO).

          -  Eastern Cooperative Oncology Group (ECOG) performance status of â‰¤ 2.

          -  Agreement to use contraception during the study and for 90 days after the last dose of
             study drugs if sexually active and able to bear or beget children.

        Exclusion Criteria

          -  A life-threatening illness, medical condition or organ system dysfunction which, in
             the investigator's opinion, could compromise the subject's safety, interfere with the
             absorption or metabolism of study drugs, or put the study outcomes at undue risk.

          -  Central nervous system (CNS) involvement by lymphoma/leukemia

          -  Any therapeutic antibody within 4 weeks of first dose of study drugs.

          -  The time from the last dose of the most recent chemotherapy or experimental therapy to
             the first dose of study drugs is &lt; 5 times the half-life of the previously
             administered agent(s).

          -  ANC &lt; 0.5 x 10^9/L or platelet count &lt; 50 x 10^9/L unless due to disease involvement
             in the bone marrow.

          -  Creatinine &gt; 1.5 x institutional upper limit of normal (ULN); total bilirubin &gt; 1.5 x
             ULN (unless due to Gilbert's disease); and aspartate aminotransferase (AST) or alanine
             aminotransferase (ALT) &gt; 3.0 x ULN.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Lee, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Monitor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alinna Lee</last_name>
    <phone>650-591-2800</phone>
    <phone_ext>172</phone_ext>
    <email>alinna.lee@acerta-pharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Rodriguez, MHA</last_name>
    <phone>+1 650 591-4024</phone>
    <email>s.rodriguez@acerta-pharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Philidelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2014</study_first_posted>
  <last_update_submitted>February 23, 2016</last_update_submitted>
  <last_update_submitted_qc>February 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bruton tyrosine kinase inhibitor</keyword>
  <keyword>Btk</keyword>
  <keyword>B-Cell Malignancies</keyword>
  <keyword>Mantle Cell</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>CLL</keyword>
  <keyword>SLL</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Folicular</keyword>
  <keyword>Waldenstrom</keyword>
  <keyword>B-All</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

